Get started

Biotech

PCI Biotech $PCIB.OL testing breakout from yearlong downtrendPCI Biotech Holding OSL:PCIB stock has been consolidating in a trading range below last years 30 NOK shareprice rights issue of NOK 360 million. Positive market reaction to the latest quarterly report from the company, along with good coverage in magasines: www.tu.no (norwegian language) nordiclifescience.org (page 91-94) At the moment, the stock is testing a breakout from the old trading range, and longs will be keen to see further conference or scientific journal coverage of the ongoing clinical programs for the companys FimaCHEM and FimaVACC products, as well as partnering deals for its FimaNAC product.
OSL:PCIBLong
by savepiginvest
The Conformis Come-BackConformis Inc. (Nasdaq: CFMS) is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture & sell patient specific joint replacement implants. The implants are designed to fit each patient's unique anatomy. CFMS stated in their previous ER (July 31, 2019), the company was updating their 2019 outlook to have "generally flat year-over-year product revenue growth for the full year 2019." The 'expected decrease in growth' was primarily due to denials in coverage from Aetna, the 3rd largest commercial payer. During the conference call, CFMS said they had "submitted its clinical and economic data to Aetna and understands that Aetna is currently reviewing its medical coverage policy." During the conference call, Conformis CEO suggested a potential update was coming this September from Aetna. As we approach mid-month, price has held 50 retracement from the lower-high made on August 28, 2019 ($2.33 ). Conformis stated that the letter denying coverage from Aetna only referred to Conformis as a company, rather than a product denial per usual standards. If Aetna did make a mistake and is willing to cover the Conformis custom joint replacements, this could bring massive upside to the current stock price.I am forecasting a $5 PT (assuming CFMS gets Aetna coverage as they did with Cigna before). Data from July 2019 10-K Market Cap: $137.357 Million Cash : $20.66 Million Revenue (product and royalty): $19.593 Million YoY Rev: +3% 52 Week High: $4.83 Ave Vol(10 Day): 628,900 Shares Outstanding: 68.68 Million Shares Float: 50.01 Million Technical's As shown in the previous chart , CFMS is positioned for a breakout. Price has continued to hold the 50% retracement from the Aug. 28, 2019 high. Previous patterns from January 2019 show similar price movement (trend-line in blue), indicating a "new" uptrend in the making. -Bullish Gartley in tact; -Aligning Fib time-cycles; -RSI approaching breakout level; -Our proprietary indicator showing strong momentum going into tomorrow's trading session (Flips green = Bullish AF), Weekly flashing bullish signal. Conclusion Potential of medicare approval for total knee replacement at surgery centers in 2020 is a huge opportunity as baby boomer population grows. The Aetna reimbursement issue will pass (as Cigna did). The soon to be released total hip system is being undervalued by the market. I am forecasting a $5 PT foregoing CFMS getting Aetna coverage. To read more of my analysis on CFMS visit our site, here . Please like and follow so I can continue finding awesome charts! Thanks in advance team d+) Disclosure: I am long CFMS. This is not a note to buy or sell. Please do your homework before investing.
CLong
by follow_the_money
Neurocrine Biosciences (NBIX) Looking to Breakout HigherBefore a major cup and handle forms, it often forms a half cup or rounded bottom that signals a more back toward former highs. It can be an early entry into a really large move if the stock breaks above former highs, or it can simply provide a swing trade which rides the momentum up into the prior high region. The target for the trade provides for an exit just below the prior high, since the price may consolidate there. Alternatively, a trailing stop loss could be used in case the price flies through the prior high and keeps going. In either case, the risk/reward is attractive here. The last patterns like this played out in 2012 into early 2013, and then again in 2014. Disclosure: Entering long this week, assuming the price action remains strong.
NASDAQ:NBIXLong
by CoryMitchell-CMT
1
Slow Churn Higher Or Another Pause For BLCM?"Since August 21st, Bellicum’s stock has made a very strong rally on the back of news releases. The price of the biotech penny stock is up nearly over 30% since the beginning of the month. This gain and volume increase came initially following the company’s $140 million public offering on the 21st. Bellicum is also participating in 3 healthcare investor conferences throughout September." Source: A List Of Penny Stocks To Watch As They Approach September Highs pennystocks.com And I understand how speculation could play a role. However, there's less volume now compared to a few weeks ago and it's approaching a level that also falls in line with previous levels it was at before.
B
by PennyStocks101
AVEO Fake Out? Or Consolidation Before Another Breakout?Aveo recently announced that the Tivozanib drug , in its second analysis, showed an improved survival hazard ratio. This penny stock news prompted the company’s stock to fly over 60% from Monday’s opening bell to Tuesday’s premarket high of $1.10. But just as quickly as it jumped, AVEO pulled back aggressively during the last 30 minutes of trading on September 10. Good Phase 3 news? Seemingly so but will profit taking crush the hopes of this breaking beyond $1 for good? Chart indicates possible technical levels and it seems that around today's high is one of those levels. "Biopharmaceutical company, Aveo Pharmaceuticals Inc. ( AVEO ) is pursuing treatment plans for different tumors. The company has 4 treatment plans in clinical trials and 2 additional ones undergoing pre-trials. Aveo’s lead product, Tivozanib, has completed the clinical trials and has been filed and marketed." Source: A List Of Penny Stocks To Watch As They Approach September Highs
A
by PennyStocks101
Bullish GartleyAbout CFMS Conformis, Inc. (NASDAQ: CFMS), is a medical device/ technology company that uses its proprietary iFit 'Image-to-Implant' technology platform to develop, manufacture and sell patient specific joint replacement implants that are designed to fit each patient's unique anatomy. Technicals Bullish Gartley pattern (786 retracement) Fibonacci confluence at the 1.272 extension 382 continuation pattern (Keeps bouncing off and making higher lows-- if it continues it could be used to further add) In-line with Fibonacci time-cycles RSI pushing higher on Daily and Weekly Potential gap up to fill up to the $2.75 level. Conclusion : CFMS has sufficient funds, great management and recently received some 510 certifications while broader markets were selling off. Looking to re-claim those prior gains. Will revisit the trade at or around time of the gap filling. Like and follow so I can continue finding awesome charts and trades. Thank you in advance d+) Twitter + Instagram @VolatilityWatch Disclosure: I am long CFMS. This is not a note to buy or sell, please do your homework before investing.
CLong
by follow_the_money
Bullish SharkLeap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly. As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent. The technical's are now aligning with some key dates with a potential short squeeze on its way (assuming good data). $LPTX is trading at the lower end of the long-term trading range. Bullish harmonic shark pattern, look for profit taking and/ or chances to add at the 382 and 50 retracement levels to ride up to the top of the range. Not only does this trade have massive upside potential for a swing trade, it is also showing confluence with Fibonacci time-cycles, fib-retracement and trend. Tip of the day: Learning how to be disciplined is vital to trading volatility. Follow our trading team for ideas on how to stay more disciplined in biotech. Disclosure: I have no position in LPTX. I may buy or sell in the next 72 hours. This is not a note to but or sell. Please do your homework before investing.
NASDAQ:LPTXLong
by follow_the_money
Can MRNS go the distance this week?"On Tuesday, the company earned attention from analysts at H.C. Wainwright. The research firm initiated coverage on MRNS stock. It gave the company a “BUY” rating as well as a price target of $5 per share. This was the 3rd analyst firm to initiate coverage on the stock this year. Previous to H.C. Wainwright, Jefferies and Leerink Swann both initiated coverage with “BUY” and “Outperform” ratings, respectively, for the penny stock. The two other firms also..." 3 Penny Stocks Making New Highs In September NASDAQ:MRNS
M
by PennyStocks101
ABEO Stock To Watch (But For How Long?)ABEO stock has been beaten down for much of 2019. It had declined by as much as 80% since the beginning of the year. It went on to emerge as one of the biggest gainers in the market yesterday. The company announced that it was going to explore options that could unlock value for the shareholders. It stated that even an outright sale or a takeover is being considered. However, volume has been cut down dramatically on Wednesday compared to Tuesday's volume. How long can the run sustain and what will come of ABEO later this month? 3 Penny Stocks Making New Highs In September NASDAQ:ABEO
NASDAQ:ABEO
by PennyStocks101
NTEC Jumped above $0.70 since falling apartWhat are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move? "Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in its pipeline with AP-CD/LD in Phase 3 trials.Over the last 2 trading sessions, Intec’s stock price has seen significant gains. On August 27th the stock price rose 14.8% and in premarket trading, on the 28th it has risen another 15%. These percentage gains allowed the biotech penny stock to go from $0.45 to $0.61." Original Article: 4 Penny Stocks To Watch Under $4 NASDAQ:NTEC
N
by PennyStocks101